Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: An analysis from the SIGNIFY study

European Heart Journal

Volumn 36, Issue 46, 2015, Pages 3291-3296

  Fox, Kim ^a   Ford, Ian ^b   Steg, Philippe Gabriel ^a,c,d,e   Tardif, Jean Claude ^f   Tendera, Michal ^g   Ferrari, Roberto ^h,i  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BICHAT HOSPITAL   (France)

^d Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f MONTREAL HEART INSTITUTE   (Canada)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h UNIVERSITY HOSPITAL OF FERRARA   (Italy)

ⁱ MARIA CECILIA HOSPITAL   (Italy)

Author keywords

Adverse event; Angina; Atrial fibrillation; Bradycardia; CAD; Ivabradine

Indexed keywords

IVABRADINE; PLACEBO; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ADULT; ANGINA PECTORIS; ARTICLE; ATRIAL FIBRILLATION; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTING HEART RATE; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

AGED; ATRIAL FIBRILLATION; BENZAZEPINES; BRADYCARDIA; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84951035400     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv451     Document Type: Article

References (13)

1. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014;371:1091-1099.
2. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J 2013;166:654-661.
3. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816.
4. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006;53:399-406.
5. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014;114:1453-1468.
6. Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kaab S, Abergel H, Fox KM, Ferrari R. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J 2012;33:2831-2840.
7. Zielonka A, Tkaczyszyn M, Mende M, Nowak W, Rekucki K, Soczomski P, Zielinski M, Pociupany R, Wilkins A, BanasiakW, Ponikowski P, Jankowska EA. Atrial fibrillation in outpatients with stable coronary artery disease-results from multicenter RECENT study. Pol Arch Med Wewn 2015;125:162-171.
8. Cameron A, Schwartz MJ, Kronmal RA, Kosinski AS. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 1988;61:714-717.
9. Lokshyn S, Mewis C, Kuhlkamp V. Atrial fibrillation in coronary artery disease. Int J Cardiol 2000;72:133-136.
10. Steg PG, Ferrari R, Ford I, Greenlaw N, Tardif JC, Tendera M, Abergel H, Fox KM. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One 2012;7:e36284.
11. Camm AJ, Lip GY, De CR, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
12. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De CR, De SJ, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
13. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-847.